Biostar Pharmaceuticals received local approval for three TCM products, which it expects to begin selling later this month. The company projects a total of $3.5 million in revenues from the three products in 2009, and $7.4 million in 2010. Biostar anticipates they will produce net income of $1 million this year and $2 million in 2010. More details...
Stock Symbol: (OTCBB: BSPM)
Sorry... this feature or article is only available to subscribers.